冠状动脉旁路移植术后抗血栓治疗:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入20项随机对照试验共4803例患者,评估口服抗血栓药物预防大隐静脉桥血管失败的效果。中等确定性证据支持阿司匹林联合替格瑞洛(OR 0.50,95%CI 0.31至0.79,需治疗人数10)或阿司匹林联合氯吡格雷(OR 0.60,95%CI 0.42至0.86,需治疗人数19)较阿司匹林单药降低桥血管失败。不同抗血栓治疗在大出血、心肌梗死和死亡方面无强证据表明存在差异。
要点
- 与阿司匹林单药相比,阿司匹林联合替格瑞洛降低大隐静脉桥血管失败(OR 0.50,95%CI 0.31至0.79,需治疗人数10)。
- 与阿司匹林单药相比,阿司匹林联合氯吡格雷降低大隐静脉桥血管失败(OR 0.60,95%CI 0.42至0.86,需治疗人数19)。
- 不同抗血栓治疗在大出血、心肌梗死和死亡方面无强证据表明存在差异。
核心结论
- 该网状Meta分析结果提示,在阿司匹林基础上加用替格瑞洛或氯吡格雷对预防冠状动脉旁路移植术后大隐静脉桥血管失败具有重要的绝对获益。
- 术后双联抗血小板治疗应通过权衡药物干预的安全性和有效性特征与重要患者结局,为患者量身定制。
研究设计与样本
- 系统综述与网状Meta分析,检索Medline、Embase、Web of Science、CINAHL和Cochrane Library自建库至2019年1月25日。
- 纳入20项随机对照试验共4803例参与者,年龄≥18岁,接受口服抗血栓药物(抗血小板药或抗凝药)以预防冠状动脉旁路移植术后大隐静脉桥血管失败,研究9种干预措施(8种活性干预和1种安慰剂)。
主要发现
- 共鉴定3266条引文,纳入21篇文章涉及20项随机对照试验。
- 与阿司匹林单药相比,阿司匹林联合替格瑞洛降低大隐静脉桥血管失败(OR 0.50,95%CI 0.31至0.79,需治疗人数10),证据确定性中等。
- 与阿司匹林单药相比,阿司匹林联合氯吡格雷降低大隐静脉桥血管失败(OR 0.60,95%CI 0.42至0.86,需治疗人数19),证据确定性中等。
- 不同抗血栓治疗在大出血、心肌梗死和死亡方面无强证据表明存在差异。
- 使用每根桥血管数据的敏感性分析未改变效应估计值。
关键数值与推荐
- 主要疗效终点为大隐静脉桥血管失败,主要安全终点为大出血,次要终点为心肌梗死和死亡。
- 阿司匹林联合替格瑞洛对比阿司匹林单药:OR 0.50,95%CI 0.31至0.79,需治疗人数10,证据确定性中等。
- 阿司匹林联合氯吡格雷对比阿司匹林单药:OR 0.60,95%CI 0.42至0.86,需治疗人数19,证据确定性中等。
临床怎么用
- 该网状Meta分析结果提示,在阿司匹林基础上加用替格瑞洛或氯吡格雷对预防冠状动脉旁路移植术后大隐静脉桥血管失败具有重要的绝对获益。
- 术后双联抗血小板治疗应通过权衡药物干预的安全性和有效性特征与重要患者结局,为患者量身定制。
局限性
- 不能排除存在不可传递性的可能。
- 所有纳入分析中试验间异质性和不一致性均较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effects of different oral antithrombotic drugs that prevent saphenous vein graft failure in patients undergoing coronary artery bypass graft surgery. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Medline, Embase, Web of Science, CINAHL, and the Cochrane Library from inception to 25 January 2019. ELIGIBILITY CRITERIA: for selecting studies Randomised controlled trials of participants (aged ≥18) who received oral antithrombotic drugs (antiplatelets or anticoagulants) to prevent saphenous vein graft failure after coronary artery bypass graft surgery. MAIN OUTCOME MEASURES: The primary efficacy endpoint was saphenous vein graft failure and the primary safety endpoint was major bleeding. Secondary endpoints were myocardial infarction and death. RESULTS: This review identified 3266 citations, and 21 articles that related to 20 randomised controlled trials were included in the network meta-analysis. These 20 trials comprised 4803 participants and investigated nine different interventions (eight active and one placebo). Moderate certainty evidence supports the use of dual antiplatelet therapy with either aspirin plus ticagrelor (odds ratio 0.50, 95% confidence interval 0.31 to 0.79, number needed to treat 10) or aspirin plus clopidogrel (0.60, 0.42 to 0.86, 19) to reduce saphenous vein graft failure when compared with aspirin monotherapy. The study found no strong evidence of differences in major bleeding, myocardial infarction, and death among different antithrombotic therapies. The possibility of intransitivity could not be ruled out; however, between-trial heterogeneity and incoherence were low in all included analyses. Sensitivity analysis using per graft data did not change the effect estimates. CONCLUSIONS: The results of this network meta-analysis suggest an important absolute benefit of adding ticagrelor or clopidogrel to aspirin to prevent saphenous vein graft failure after coronary artery bypass graft surgery. Dual antiplatelet therapy after surgery should be tailored to the patient by balancing the safety and efficacy profile of the drug intervention against important patient outcomes. STUDY REGISTRATION: PROSPERO registration number CRD42017065678.
引用
- Solo K, Lavi S, Kabali C, et al. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ. 2019. PMID: 31601578. doi:10.1136/bmj.l5476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。